首页> 美国卫生研究院文献>Journal of Cellular and Molecular Medicine >Secretion of annexin A3 from ovarian cancer cells and its association with platinum resistance in ovarian cancer patients
【2h】

Secretion of annexin A3 from ovarian cancer cells and its association with platinum resistance in ovarian cancer patients

机译:卵巢癌细胞中膜联蛋白A3的分泌及其与铂耐药的关系

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Early detection of resistance to platinum-based therapy is critical for improving the treatment of ovarian cancers. We have previously found that increased expression of annexin A3 is a mechanism for platinum resistance in ovarian cancer cells. Here we demonstrate that annexin A3 can be detected in the culture medium of ovarian cancer cells, particularly these cells that express high levels of annexin A3. Levels of annexin A3 were then determined in sera from ovarian cancer patients using an enzyme-linked immunosorbent assay. Compared with those from normal donors, sera from ovarian cancer patients contain significantly higher levels of annexin A3. Furthermore, serum levels of annexin A3 were significantly higher in platinum-resistant patients than in platinum-sensitive patients. To gain insight into the mechanism of secretion, the ovarian cancer cell lines were examined using both transmission electron microscopy and immunoelectron microscopy. Compared with parent cells, there are significantly more vesicles in the cytoplasm of ovarian cancer cells that express high levels of annexin A3, and at least some vesicles are annexin A3-positive. Moreover, some vesicles appear to be fused with the cell membrane, suggesting that annexin A3 secretion may be associated with exocytosis and the release of exosomes. This is supported by our observation that ovarian cancer cells expressing higher levels of annexin A3 released increased numbers of exosomes. Furthermore, annexin A3 can be detected in exosomes released from cisplatin-resistant cells (SKOV3/Cis) by immunoblotting and immunoelectron microscopy.
机译:早期发现对铂类疗法的耐药性对于改善卵巢癌的治疗至关重要。我们先前已经发现,膜联蛋白A3的表达增加是卵巢癌细胞中铂耐药的机制。在这里,我们证明可以在卵巢癌细胞的培养基中检测到膜联蛋白A3,特别是这些表达高水平膜联蛋白A3的细胞。然后使用酶联免疫吸附测定法测定卵巢癌患者血清中的膜联蛋白A3水平。与正常供体相比,卵巢癌患者血清中的膜联蛋白A3水平明显更高。此外,铂类耐药患者的血清膜联蛋白A3水平明显高于铂类敏感患者。为了深入了解分泌的机制,使用透射电子显微镜和免疫电子显微镜检查了卵巢癌细胞系。与亲代细胞相比,卵巢癌细胞的细胞质中有大量的囊泡表达高水平的膜联蛋白A3,并且至少一些囊泡是膜联蛋白A3阳性的。此外,一些囊泡似乎与细胞膜融合,表明膜联蛋白A3的分泌可能与胞吐作用和外泌体的释放有关。我们的观察结果支持了这一点,即表达较高水平的膜联蛋白A3的卵巢癌细胞释放的外泌体数量增加。此外,通过免疫印迹和免疫电子显微镜可以检测到顺铂耐药细胞(SKOV3 / Cis)释放的外泌体中的膜联蛋白A3。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号